Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

Summary

This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.

Timeline

Start

2015-08

Primary completion

2016-05-06

Completion

2017-03

Outcome

Met primary endpoint

release “today reported topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab (Humira®) biosimilar candidate. This study met its primary endpoint” coherus.com ↗

Drugs

Indications